 Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why 
The world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t seen in America for more than a century. For the full story, click here.
More Reading from MarketBeat Media BioTech Breakout: MoonLake Up 30% On FDA WinsBy Jeffrey Neal Johnson. Date Posted: 2/3/2026. 
Article Highlights- The FDA recently granted Fast Track designation to MoonLake Immunotherapeutics' lead drug for a severe skin condition while clearing the path for a major filing.
- Management maintains a robust balance sheet that provides a cash runway extending well into the future to support ongoing clinical development plans.
- Rising share prices and upcoming data readouts could pressure short sellers who bet against the stock now that the period of uncertainty has passed.
With markets focused on interest-rate cuts and the artificial intelligence (AI) boom, it's easy to overlook the biotechnology sector. Yet for investors willing to look beyond the Magnificent Seven, clinical-stage biotech remains one of the few places to find large, event-driven returns that are largely independent of the broader economy. MoonLake Immunotherapeutics (NASDAQ: MLTX) is proving that in real time. The stock jumped roughly 10% in the first trading days of February, pushing its price above $16, and is up more than 30% over the last month. While volatility is the price of admission in this sector, MoonLake's recent rally is not built on hype. It's driven by a series of concrete regulatory wins that materially change the company's outlook. Clearing a Path: The Month of Regulatory WinsWatch Now! Porter Stansberry & Luke Lango join forces to unveil:
The Three Titanic Forces Converging To Unleash A New 1776 Moment
"We have never seen wealth created at this size and speed" MIT Researcher Click here for the stocks to buy and sell now The catalyst for the latest rally arrived on Feb. 2, 2026, when the U.S. Food and Drug Administration (FDA) granted Fast Track designation to MoonLake's lead drug, Sonelokimab, for the treatment of Palmoplantar Pustulosis (PPP). PPP is a severe, chronic skin condition that causes painful pustules on the palms and soles. There are currently no approved treatments for PPP in the United States, representing a significant unmet need. Fast Track is more than a buzzword. It is a formal FDA designation for drugs that address serious conditions and show the potential to meet an unmet medical need. It provides two concrete advantages: - Access: More frequent interactions with the FDA help ensure the company stays on the right development path and avoids wasted time and expense.
- Speed: Fast Track allows for rolling submission of completed sections of a drug application, enabling parts of the filing to be reviewed immediately rather than waiting for the entire dossier. That can shave months off the approval timeline.
That news followed an even bigger victory. On Jan. 8, 2026, the company announced the results of a critical Type B meeting with the FDA about its primary disease target, Hidradenitis Suppurativa (HS). MoonLake's stock had crashed in 2025 after mixed HS trial results, and investors feared the FDA might demand a new, costly multi-year study. Instead, the FDA confirmed that the existing data are sufficient to file for approval. That was a major de-risking event. By clearing the path for HS and granting Fast Track for PPP, the agency effectively validated MoonLake's underlying Nanobody platform. Nanobodies are smaller than traditional antibodies and can penetrate inflamed tissue more effectively. Success across multiple indications suggests the platform is robust, shifting MoonLake from a high-risk bet to a company with a viable pipeline. Cash Is King: Funded Through 2027Biotech investors often brace for dilution, because smaller companies commonly issue new shares after price rallies to raise capital, which can dilute existing holders. MoonLake is in a strong financial position. According to its third-quarter 2025 financial report, the company held about $380.5 million in cash, cash equivalents, and short-term securities. At the current burn rate, that runway extends into the second half of 2027. That balance-sheet strength is a key part of the bull case. It gives MoonLake the time and resources to complete regulatory filings and move toward commercialization without immediately returning to the market for capital. Management can therefore prioritize execution over fundraising, reducing the near-term risk of a dilutive secondary offering. Skeptics vs. Momentum: The Setup for a RallyEven with regulatory progress and a healthy cash position, skepticism remains. As of mid-January 2026, short interest in MoonLake had risen to about 12.7% of the available shares. Short sellers—who bet on a stock's decline—likely built those positions in late 2025, when the company was navigating uncertainty around its HS data. Those traders expected operational hurdles or dilution to compress the share price. The recent favorable FDA interactions challenge that bearish thesis. If positive momentum continues and the share price rises, short sellers will face losses and may be forced to cover by buying shares, which can amplify the rally. With roughly 12.7% of the float sold short, there is meaningful potential for this dynamic to accelerate MoonLake's recovery. Investor Day Preview: The Next Big MoverThe recent surge may be just the opening act. MoonLake has confirmed an Investor Day for Feb. 23, 2026, which should provide the next potential catalyst. The event will feature a data readout from the Phase 2 S-OLARIS trial, which tests Sonelokimab in a third indication: Axial Spondyloarthritis (axSpA), an inflammatory arthritis of the spine. Positive results would add another indication to the program and further validate the drug across multiple inflammatory diseases. Looking further ahead, the company expects to report 52-week HS data in the second quarter of 2026, with a Biologics License Application (BLA) submission anticipated in the second half of the year. Risk, Reward, and Regulatory AlphaMoonLake Immunotherapeutics has navigated the perilous stretch that sinks many early-stage biotech firms. Securing a clear approval path for HS and Fast Track status for PPP meaningfully reduces development risk. While commercial execution, pricing, and competition remain uncertainties, the combination of regulatory clarity, a strong balance sheet, and a skeptical market positioned for a squeeze makes MoonLake one of the more interesting stories in biotech. For investors seeking idiosyncratic growth, MoonLake Immunotherapeutics is worth watching closely in 2026.
This ad is sent on behalf of Banyan Hill Publishing. P.O. Box 8378, Delray Beach, FL 33482. | 
No comments:
Post a Comment